Mikkel Illemann Johansen , Maiken Engelbrecht Petersen , Emma Faddy , Anders Marthinsen Seefeldt , Alexander Alexandrovich Mitkin , Lars Østergaard , Rikke Louise Meyer , Nis Pedersen Jørgensen
{"title":"利福平联合疗法对大鼠模型中 MRSA 假体血管移植感染的疗效","authors":"Mikkel Illemann Johansen , Maiken Engelbrecht Petersen , Emma Faddy , Anders Marthinsen Seefeldt , Alexander Alexandrovich Mitkin , Lars Østergaard , Rikke Louise Meyer , Nis Pedersen Jørgensen","doi":"10.1016/j.bioflm.2024.100189","DOIUrl":null,"url":null,"abstract":"<div><p><em>Staphylococcus aureus</em> is a major cause of prosthetic vascular graft or endograft infections (VGEIs) and the optimal choice of antibiotics is unclear. We investigated various antibiotic choices as either monotherapy or combination therapy with rifampicin against MRSA <em>in vitro</em> and <em>in vivo</em>.</p><p>Fosfomycin, daptomycin and vancomycin alone or in combination with rifampicin was used against MRSA USA300 FPR3757. Each antibiotic was tested for synergism or antagonism with rifampicin <em>in vitro,</em> and all antibiotic regimens were tested against actively growing bacteria in media and non-growing bacteria in buffer, both as planktonic cells and in biofilms. A rat model of VGEI was used to quantify the therapeutic efficacy of antibiotics <em>in vivo</em> by measuring bacterial load on grafts and in spleen, liver and kidneys.</p><p><em>In vitro,</em> rifampicin combinations did not reveal any synergism or antagonism in relation to growth inhibition. However, quantification of bactericidal activity revealed a strong antagonistic effect, both on biofilms and planktonic cells. This effect was only observed when treating active bacteria, as all antibiotics had little or no effect on inactive cells. Only daptomycin showed some biocidal activity against inactive cells. <em>In vivo</em> evaluation of therapy against VGEI contrasted the <em>in vitro</em> results<em>.</em> Rifampicin significantly increased the efficacy of both daptomycin and vancomycin. The combination of daptomycin and rifampicin was by far the most effective, curing 8 of 13 infected animals.</p><p>Our study demonstrates that daptomycin in combination with rifampicin shows promising potential against VGEI caused by MRSA. Furthermore, we show how <em>in vitro</em> evaluation of antibiotic combinations in laboratory media does not predict their therapeutic effect against VGEI <em>in vivo</em>, presumably due to a difference in the metabolic state of the bacteria.</p></div>","PeriodicalId":55844,"journal":{"name":"Biofilm","volume":"7 ","pages":"Article 100189"},"PeriodicalIF":5.9000,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590207524000145/pdfft?md5=e95db5a749838693e3087c7d7413e390&pid=1-s2.0-S2590207524000145-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Efficacy of rifampicin combination therapy against MRSA prosthetic vascular graft infections in a rat model\",\"authors\":\"Mikkel Illemann Johansen , Maiken Engelbrecht Petersen , Emma Faddy , Anders Marthinsen Seefeldt , Alexander Alexandrovich Mitkin , Lars Østergaard , Rikke Louise Meyer , Nis Pedersen Jørgensen\",\"doi\":\"10.1016/j.bioflm.2024.100189\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><em>Staphylococcus aureus</em> is a major cause of prosthetic vascular graft or endograft infections (VGEIs) and the optimal choice of antibiotics is unclear. We investigated various antibiotic choices as either monotherapy or combination therapy with rifampicin against MRSA <em>in vitro</em> and <em>in vivo</em>.</p><p>Fosfomycin, daptomycin and vancomycin alone or in combination with rifampicin was used against MRSA USA300 FPR3757. Each antibiotic was tested for synergism or antagonism with rifampicin <em>in vitro,</em> and all antibiotic regimens were tested against actively growing bacteria in media and non-growing bacteria in buffer, both as planktonic cells and in biofilms. A rat model of VGEI was used to quantify the therapeutic efficacy of antibiotics <em>in vivo</em> by measuring bacterial load on grafts and in spleen, liver and kidneys.</p><p><em>In vitro,</em> rifampicin combinations did not reveal any synergism or antagonism in relation to growth inhibition. However, quantification of bactericidal activity revealed a strong antagonistic effect, both on biofilms and planktonic cells. This effect was only observed when treating active bacteria, as all antibiotics had little or no effect on inactive cells. Only daptomycin showed some biocidal activity against inactive cells. <em>In vivo</em> evaluation of therapy against VGEI contrasted the <em>in vitro</em> results<em>.</em> Rifampicin significantly increased the efficacy of both daptomycin and vancomycin. The combination of daptomycin and rifampicin was by far the most effective, curing 8 of 13 infected animals.</p><p>Our study demonstrates that daptomycin in combination with rifampicin shows promising potential against VGEI caused by MRSA. Furthermore, we show how <em>in vitro</em> evaluation of antibiotic combinations in laboratory media does not predict their therapeutic effect against VGEI <em>in vivo</em>, presumably due to a difference in the metabolic state of the bacteria.</p></div>\",\"PeriodicalId\":55844,\"journal\":{\"name\":\"Biofilm\",\"volume\":\"7 \",\"pages\":\"Article 100189\"},\"PeriodicalIF\":5.9000,\"publicationDate\":\"2024-02-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2590207524000145/pdfft?md5=e95db5a749838693e3087c7d7413e390&pid=1-s2.0-S2590207524000145-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biofilm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590207524000145\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biofilm","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590207524000145","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
Efficacy of rifampicin combination therapy against MRSA prosthetic vascular graft infections in a rat model
Staphylococcus aureus is a major cause of prosthetic vascular graft or endograft infections (VGEIs) and the optimal choice of antibiotics is unclear. We investigated various antibiotic choices as either monotherapy or combination therapy with rifampicin against MRSA in vitro and in vivo.
Fosfomycin, daptomycin and vancomycin alone or in combination with rifampicin was used against MRSA USA300 FPR3757. Each antibiotic was tested for synergism or antagonism with rifampicin in vitro, and all antibiotic regimens were tested against actively growing bacteria in media and non-growing bacteria in buffer, both as planktonic cells and in biofilms. A rat model of VGEI was used to quantify the therapeutic efficacy of antibiotics in vivo by measuring bacterial load on grafts and in spleen, liver and kidneys.
In vitro, rifampicin combinations did not reveal any synergism or antagonism in relation to growth inhibition. However, quantification of bactericidal activity revealed a strong antagonistic effect, both on biofilms and planktonic cells. This effect was only observed when treating active bacteria, as all antibiotics had little or no effect on inactive cells. Only daptomycin showed some biocidal activity against inactive cells. In vivo evaluation of therapy against VGEI contrasted the in vitro results. Rifampicin significantly increased the efficacy of both daptomycin and vancomycin. The combination of daptomycin and rifampicin was by far the most effective, curing 8 of 13 infected animals.
Our study demonstrates that daptomycin in combination with rifampicin shows promising potential against VGEI caused by MRSA. Furthermore, we show how in vitro evaluation of antibiotic combinations in laboratory media does not predict their therapeutic effect against VGEI in vivo, presumably due to a difference in the metabolic state of the bacteria.